[1]杜娟英,薛海鲸.多发性骨髓瘤患者血清微小RNA-424、可溶性晚期糖基化终末产物受体、c-kit受体蛋白检测及临床意义[J].陕西医学杂志,2022,51(12):1585-1588,1592.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.028]
　DU Juanying,XUE Haijing.Detection and clinical significance of serum miR-424,sRAGE and CD117 in patients with multiple myeloma[J].,2022,51(12):1585-1588,1592.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.028]
点击复制

多发性骨髓瘤患者血清微小RNA-424、可溶性晚期糖基化终末产物受体、c-kit受体蛋白检测及临床意义
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年12期
页码:
1585-1588,1592
栏目:
临床检验
出版日期:
2022-12-05

文章信息/Info

Title:
Detection and clinical significance of serum miR-424,sRAGE and CD117 in patients with multiple myeloma
作者:
杜娟英; 薛海鲸
(宝鸡市中心医院检验科,陕西 宝鸡 721008)
Author(s):
DU Juanying; XUE Haijing
(Department of Laboratory Medicine,Baoji Central Hospital,Baoji 721008,China)
关键词:
多发性骨髓瘤;  微小RNA-424;  可溶性晚期糖基化终末产物受体;  c-kit受体蛋白;  临床分期;  免疫分型;  肾损伤
Keywords:
Multiple myeloma;  miR-424;  Soluble receptor for advanced glycation end products;  C-kit receptor protein;  Clinical stage;  Immunophenotype;  Kidney injury
分类号:
R 733.3
DOI:
DOI:10.3969/j.issn.1000-7377.2022.12.028
文献标志码:
A
摘要:
目的:探讨多发性骨髓瘤患者血清微小RNA-424(miR-424)、可溶性晚期糖基化终末产物受体(sRAGE)、c-kit受体蛋白(CD117)检测及临床意义。方法:选择多发性骨髓瘤患者125例为观察组,另选一般资料与观察组相匹配的体检健康者125例为对照组,比较两组血清miR-424、sRAGE、CD117水平。观察不同临床分期及免疫分型多发性骨髓瘤患者血清miR-424、sRAGE、CD117水平的差异性。根据观察组患者是否合并肾损伤,分为肾损伤组和非肾损伤组,比较两组血清miR-424、sRAGE、CD117水平,并采用多因素Logistic回归分析血清miR-424、sRAGE、CD117与患者发生肾损伤的关系。结果:观察组血清miR-424、CD117水平高于对照组,sRAGE水平低于对照组(均P<0.05)。Ⅲ期患者血清miR-424、CD117水平均高于Ⅰ期和Ⅱ期患者,sRAGE水平低于Ⅰ期和Ⅱ期患者(均P<0.05)。IgG型患者血清miR-424和CD117水平高于IgA型、轻链型和非分泌型患者,sRAGE水平低于IgA型、轻链型和非分泌型患者(均P<0.05)。肾损伤组血清miR-424、sRAGE、CD117水平高于非肾损伤组(均P<0.05)。经多因素Logistic回归分析,血清miR-424、sRAGE、CD117是多发性骨髓瘤患者发生肾损伤的独立预测因素(均P<0.05)。结论:多发性骨髓瘤患者血清miR-424、CD117水平异常升高,sRAGE水平异常降低,三者与临床分期、免疫分型及肾损伤密切相关。
Abstract:
Objective:To investigate the detection and clinical significance of serum microRNA-424(miR-424),soluble receptor for advanced glycation end products(sRAGE)and c-kit receptor protein(CD117)in patients with multiple myeloma and their clinical significance.Methods:A total of 125 patients with multiple myeloma were selected as the observation group,and 125 healthy subjects with general information matching with the observation group were selected as the control group.The levels of serum miR-424,sRAGE and CD117 were compared between the two groups.The differences of serum miR-424,sRAGE and CD117 levels in patients with multiple myeloma of different clinical stages and immunophenotypes were observed.The patients in the observation group were divided into kidney injury group and non-kidney injury group according to whether the patients were complicated with kidney injury,and the levels of serum miR-424,sRAGE and CD117 in the two groups were compared,and the relationship between serum miR-424,sRAGE,CD117 and kidney injury was analyzed by multivariate Logistic regression.Results:The levels of serum miR-424 and CD117 in the observation group were higher than those in the control group,while the level of sRAGE was lower than that in the control group(all P<0.05).The serum levels of miR-424 and CD117 in stage Ⅲ patients were higher than those in stage Ⅰ and Ⅱ patients,and sRAGE levels were lower than those in stage Ⅰ and Ⅱ patients(all P<0.05).Serum miR-424 and CD117 levels were higher in patients with IgG type than those in patients with IgA type,light chain type and non-secretory type,and sRAGE levels were lower than those in patients with IgA type,light chain type and non-secretory(all P<0.05).The levels of serum miR-424,sRAGE and CD117 in renal injury group were higher than those in non-renal injury group(all P<0.05).Multivariate Logistic regression analysis showed that serum miR-424,sRAGE and CD117 were independent predictors of kidney injury in patients with multiple myeloma(all P<0.05).Conclusion:Serum levels of miR-424 and CD117 in patients with multiple myeloma are abnormally increased,and sRAGE level is abnormally decreased,which are closely related to clinical stage,immunophenotype and kidney injury.

参考文献/References:

[1] 王 椋,徐 敏,邢 健,等.MiR-144调控Wnt4/β-catenin信号通路抑制多发性骨髓瘤细胞恶性生物学行为的研究[J].中国实验血液学杂志,2020,28(4):1256-1260.
[2] 朱清红,李德奎,罗 英.血清尿酸、β<sup>2微球蛋白和尿液轻链联合检测在多发性骨髓瘤早期诊断中的应用[J].陕西医学杂志,2019,48(9):1235-1237.
[3] 靳娟娟,姚 玉.MutT同系物1抑制剂对多发性骨髓瘤细胞增殖和凋亡的影响[J].陕西医学杂志,2021,50(8):934-936,948.
[4] 黄娟娟,卓 芬,蔡月红,等.血清miR-424及miR-765在多发性骨髓瘤中的表达及其临床意义[J].中国实验血液学杂志,2022,30(2):461-465.
[5] Kashif M,Alici E,Nahi H.Predicting drug resistance by single-cell RNASeq in patients with multiple myeloma[J].Clin Chem,2021,67(10):1309-1311.
[6] 曲 璟,肖 斌,李林海,等.多发性骨髓瘤合并肾损伤的实验室特征[J].实用医学杂志,2021,37(15):2003-2006,2011.
[7] 李迎巧,高二超,王茂生.杨淑莲治疗多发性骨髓瘤经验[J].陕西中医,2022,43(5):628-631,652.
[8] Yamagishi SI.Role of advanced glycation endproduct(AGE)-receptor for advanced glycation endproduct(RAGE)axis in cardiovascular disease and its therapeutic intervention[J].Circulation Journal,2019,83(9):1822-1828.
[9] 王辰辰,张倩倩,李 静,等.化痰活血方治疗痰瘀痹阻型多发性骨髓瘤疗效及对患者血管内皮生长因子的影响[J].陕西中医,2022,43(5):588-591.
[10] Adamia S,Abiatari I,Amin SB,et al.The effects of microRNA deregulation on pre-RNA processing network in multiple myeloma[J].Leukemia,2019,34(1):167-179.
[11] 王 娟,曾爱明,梁树芬.血清HMGB1、sRAGE在初诊多发性骨髓瘤的诊断、疗效监测及预后中的价值[J].中国实验血液学杂志,2022,30(2):493-500.
[12] 林火真,马春蓉.初诊多发性骨髓瘤患者CD28、CD34及CD117的表达水平及临床意义[J].标记免疫分析与临床,2020,27(4):582-585,594.
[13] 侯艳军,张秋怡,单志娟,等.多发性骨髓瘤患者骨髓中CD56和CD117水平表达对评估疾病预后的价值[J].现代检验医学杂志,2021,36(6):74-77.
[14] 黄 垚,刘 烨.CD56、CD117在多发性骨髓瘤中的表达及其与临床病理特征的相关性[J].实用癌症杂志,2019,34(4):530-533.
[15] Elizabeth G,Armando RR,Luisa L,et al.Association of receptor for advanced glycation end product(RAGE)gene polymorphisms and serum levels of soluble RAGE(sRAGE)with metabolic syndrome(MS)in mexican population[J].American Heart Journal,2020,229(10):158.
[16] Ryszczyńska B,Budzyń M,Begier-Krasińska B,et al.Association between advanced glycation end products,soluble RAGE receptor,and endothelium dysfunction,evaluated by circulating endothelial cells and endothelial progenitor cells in patients with mild and resistant hypertension[J].International Journal of Molecular Sciences,2019,20(16):3942.
[17] 孙 欢,杜 燕,徐陆忠,等.CD56、CD117表达水平与来那度胺治疗多发性骨髓瘤疗效的相关性分析[J].现代生物医学进展,2020,20(1):72-75.
[18] 黄昭萍,杨灿华.老年多发性骨髓瘤合并肾损伤患者的病理特征及危险因素分析[J].中国医药,2021,16(3):417-421.
[19] 许德英,孙真真,王小利,等.初诊中性粒细胞与淋巴细胞比值、淋巴细胞亚群及免疫分型对多发性骨髓瘤患者总生存时间的影响[J].中国实验诊断学,2020,24(5):722-726.
[20] Lim A,Radujkovic A,Weigand MA,et al.Soluble receptor for advanced glycation end products(sRAGE)as a biomarker of COVID-19 disease severity and indicator of the need for mechanical ventilation,ARDS and mortality[J].Annals of Intensive Care,2021,11(1):50.
[21] 时 杰,孙 恺,朱尊民,等.CD56和(或)CD117表达在以硼替佐米为基础一线治疗的初诊多发性骨髓瘤患者中的预后意义[J].中华血液学杂志,2019,40(8):693-696.

相似文献/References:

[1]朱清红,李德奎,罗 英.血清尿酸、β2微球蛋白和尿液轻链联合检测〖JZ〗在多发性骨髓瘤早期诊断中的应用[J].陕西医学杂志,2019,(9):1235.
　ZHU Qinghong,LI Dekui,LUO Ying..Combined detection of serum uric acid，β2 microglobulin and urine light chain〖JZ〗in early diagnosis of multiple myeloma[J].,2019,(12):1235.
[2]靳娟娟,姚 玉.MutT同系物1抑制剂对多发性骨髓瘤细胞增殖和凋亡的影响[J].陕西医学杂志,2021,50(8):934.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.008]
　JIN Juanjuan,YAO Yu.Effect of MutT homologue-1 inhibitor on proliferation and apoptosis of multiple myeloma cells[J].,2021,50(12):934.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.008]
[3]张治业,余醒醒,张 璐,等.CD166对多发性骨髓瘤RPMI-8226细胞增殖、凋亡及自噬的影响实验研究[J].陕西医学杂志,2023,52(12):1675.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.010]
　ZHANG Zhiye,YU Xingxing,ZHANG Lu,et al.Effects of CD166 on proliferation,apoptosis and autophagy of multiple myeloma RPMI-8226 cells[J].,2023,52(12):1675.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.010]
[4]刘虹伶,王美佳,晏青霞.多发性骨髓瘤患者血清β2-微球蛋白、肿瘤坏死因子-α、乳酸脱氢酶检测及临床意义[J].陕西医学杂志,2024,(3):399.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.024]
　LIU Hongling,WANG Meijia,YAN Qingxia.Detection and clinical significance of serum β2-microglobulin,tumor necrosis factor-α and lactate dehydrogenase in patients with multiple myeloma[J].,2024,(12):399.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.024]
[5]滕 远,李莉娟,张连生.髓细胞白血病1抑制剂在多发性骨髓瘤治疗中的研究进展[J].陕西医学杂志,2024,(6):858.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.029]
　TENG Yuan,LI Lijuan,ZHANG Liansheng.Research progress of myeloid cell leukemia 1 inhibitors in treatment of multiple myeloma[J].,2024,(12):858.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.029]
[6]赵思捷,余 航,党珮珠,等.多发性骨髓瘤患者合并心包积液危险因素分析及列线图预测模型构建[J].陕西医学杂志,2024,(12):1635.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.009]
　ZHAO Sijie,YU Hang,DANG Peizhu,et al.Risk factors of multiple myeloma patients with pericardial effusion and construction of nomogram prediction model[J].,2024,(12):1635.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.009]

备注/Memo

备注/Memo:
基金项目:陕西省卫生健康科研基金资助项目(2021D008)
更新日期/Last Update: 2022-12-05